Cheaper form of Merck’s COVID-19 pill to be produced for poorer nations
Category: #headlines  | By Nikita Chaurasia  | Date: 2022-01-22 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Cheaper form of Merck’s COVID-19 pill to be produced for poorer nations

Over 30 generic drugmakers from Asia, the Middle East, and Africa are reportedly developing low-cost versions of Merck's COVID-19 pill in a U.N.-backed agreement. This is being done to ensure that such drugs are available to the world's underdeveloped countries.

The Medicines Patent Pool (MPP) stated that the pill will be distributed to nearly 105 poor countries at the cost of USD 20 per course, which involves a 5-day course consisting of 40 pills.

Companies in the same sector, such as Dr. Reddy's Lab, have also struck deals with Merck for manufacturing the pill, which will be sold at USD 18.8 per course. Notably, this is a significant reduction from the original cost of USD 700 per course.

Sources claim that U.S. firms endorsing the production of the anti-viral pill Molnupiravir by other companies is a rare occurrence, as most pharmaceutical companies strive to protect their patented treatments for as long as possible.

Among the 27 drugmakers permitted to produce ingredients and the final drug under the agreement are Natco Pharma (India), Aspen Pharmacare Holdings (South Africa), Fosun Pharma (China), and Beximco Pharmaceuticals (Bangladesh) among others.

As per reports, the agreement reached by the United Nations-backed MPP with Merck and other developers such as Ridgeback Biotherapeutics and Emory University prevents the companies from receiving royalties on the sale of the cheaper version of the pill until the pandemic is over.

However, it is worth noting that Merck's Molnupiravir drug has shown less effectiveness in early clinical trials, as well as a variety of side effects, raising grave reservations about the widespread use of the drug.

It has not yet been sanctioned by WHO, resulting in a restriction on its sale in most developing countries due to a lack of regulatory resources for national authorization.

While the U.S. validated the drug in December last year, other countries are skeptical due to less-than-desirable trial results shown in efficacy trials.

Source credit:

https://www.usnews.com/news/world/articles/2022-01-20/cheap-version-of-merck-covid-pill-to-be-made-for-poorer-nations

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Urban Company introduces health insurance for service professionals

Urban Company introduces health insurance for service professionals

By Nikita Chaurasia

Urban Company, the home service firm, stated that it will offer health insurance for its service partners by collaborating with ACKO Insurance. Varun Khaitan, Chief Operating Officer and Co-Founder, Urban Company stated that health insurance offer...

EV startup Arrival launches prototype of dedicated ride-hailing car

EV startup Arrival launches prototype of dedicated ride-hailing car

By Nikita Chaurasia

British commercial electric vehicle company, Arrival, has reportedly unveiled the first prototype of its purpose-built EV for ride-hailing purposes, which was built in partnership with Uber in the UK. Avinash Rugoobur, President of Arrival, stated...

Goldman Sachs provides unlimited holidays to its senior employees

Goldman Sachs provides unlimited holidays to its senior employees

By Nikita Chaurasia

Goldman Sachs has recently announced a flexible vacation scheme under which the company’s senior employees can take unlimited paid leaves annually. As per sources, the global investment bank has unveiled a new policy that will allow senior sta...